US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
13 deals · US$2.9bndisclosed · Oncology · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Sep 2026 | Pyxis Oncology | – | – | Follow-on offering | Announced | 110.0 | Biotech+1 | Latham & Watkins (lead manager) |
| Aug 2026 | BlossomHill Therapeutics | – | – | IPO | Listed | 150.0 | Biotech+2 | Cooley (issuer)J.P. Morgan (lead manager)Leerink Partners (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)H.C. Wainwright & Co. (lead manager)Latham & Watkins (lead manager) |
| Jun 2026 | Remix Therapeutics | – | – | Placement | Pending | 100.0 | Biotech+2 | Goldman Sachs (lead manager)Jefferies (lead manager)Evercore (lead manager)Cooley (lead manager) |
| Jun 2026 | Parabilis Medicines | – | – | IPO | Listed | 670.0 | Biotech+2 | Goodwin (issuer)Leerink Partners (lead manager)BofA Securities (lead manager)Evercore (lead manager)Guggenheim Securities (lead manager)LifeSci Capital (lead manager)Covington & Burling (lead manager) |
| Jun 2026 | Avenzo Therapeutics | – | – | Placement | Pending | 215.0 | Biotech+2 | Leerink Partners (lead manager)Goldman Sachs (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Mintz (lead manager) |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Completed | 350.0 | Biotech+2 | GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager) |
| Feb 2026 | Sensei Biotherapeutics | – | – | Placement | Pending | 200.0 | Biotech+2 | Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager) |
| Feb 2026 | Liminatus Pharma | – | – | Follow-on offering | Announced | 4.0 | Biotech+2 | Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager) |
| Feb 2026 | Eikon Therapeutics | – | – | IPO | Announced | 381.2 | Oncology+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager) |
| Feb 2026 | Perspective Therapeutics | – | – | Follow-on offering | Announced | 175.0 | Radiopharmaceuticals+2 | Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager) |
| Jan 2026 | Aktis Oncology | – | – | IPO | Listed | 317.7 | Biotech+2 | Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager) |
| Dec 2025 | Freenome | – | – | Placement | Completed | 240.0 | Diagnostics+2 | Goodwin (issuer)Jefferies (lead manager)Leerink Partners (lead manager)White & Case (lead manager) |
| – | Silexion Therapeutics Corp | – | – | Follow-on offering | Announced | 2.5 | Biotech+2 | Conyers (issuer)Greenberg Traurig (issuer)H.C. Wainwright & Co. (lead manager)Ellenoff Grossman & Schole (lead manager) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built